Will clinical trial data disclosure reduce incentives to develop new uses of drugs
作者： W Nicholson Price , Timo Minssen
DOI: 10.1038/NBT.3243
关键词: Actuarial science 、 Incentive 、 Medical law 、 Intellectual property 、 Clinical trial 、 Business 、 Drug development 、 Data disclosure
摘要:
nature.com
sci-hub.se 参考文章(7)
Benjamin N. Roin, Solving the Problem of New Uses Social Science Research Network. ,(2013) , 10.2139/SSRN.2337821
Martin Westlake, The Council of the European Union ,(1995)
I. Torjesen, European drug agency backtracks on plan to give researchers access to clinical trial reports. BMJ. ,vol. 348, ,(2014) , 10.1136/BMJ.G3432
L Feldman, A Malins, J A DiMasi, J M Reichert, Clinical Approval Success Rates for Investigational Cancer Drugs Clinical Pharmacology & Therapeutics. ,vol. 94, pp. 329- 335 ,(2013) , 10.1038/CLPT.2013.117
Michelle M. Mello, Jeffrey K. Francer, Marc Wilenzick, Patricia Teden, Barbara E. Bierer, Mark Barnes, Preparing for Responsible Sharing of Clinical Trial Data The New England Journal of Medicine. ,vol. 369, pp. 1651- 1658 ,(2013) , 10.1056/NEJMHLE1309073
P. Doshi, Putting GlaxoSmithKline to the test over paroxetine BMJ. ,vol. 347, ,(2013) , 10.1136/BMJ.F6754
안태경, Social Science Research Network 월간KIEP 세계경제. ,vol. 8, pp. 0- 1 ,(2005)